Lysosomal Storage Disease Market 2018 - Opportunity, Driving Trends and deep study.

PUNE , INDIA, April 27, 2018 /EINPresswire.com/ -- Lysosomal Storage Disease (LSD) is a genetic disorder that causes various types of nervous system disorders such as clinical abnormalities and cellular dysfunction. There are more than 65 categories of LSD. This disease can be classified into Lipid Metabolism Disorder and Glycoprotein Metabolism Disorder. Further Lipid Metabolism Disorder is categorized into Gaucher disease & Fabry disease and Glycoprotein Metabolism Disorder into Pompe disease. LSD develops mainly due to deficiency of lysosomal enzyme in the living body. A person suffering from LSD could experience problems like abnormal growth of bones, delay movement of body, deafness, blindness, dementia, respiratory problems, fatigue/weakness, bone & joint deformity, organ enlargement, lung dysfunction, severe & fatal physical & mental health deterioration.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/reports/3080299-global-lysosomal-storage-disease-lsd-market-fabry-gaucher

The global LSD market is expected to grow with growing Ashkenazi (Eastern and Western Europe) population, increasing pharmaceutical R&D spending, growing disposable income, rising healthcare expenditure and accelerating economic growth. Key trends of this rare disease market includes progressing drugs under pipeline and increasing preference towards gene therapy. However, there are some factors which can hinder growth of the market including stringent regulations and limited access to patent rights.

The report “Global Lysosomal Storage Disease (LSD) Market (Fabry, Gaucher & Pompe): Industry Analysis & Outlook (2018-2022)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook.

The report discusses the major growth drivers, key tends & developments and challenges of the market, covering the global market. The report profiles the key players of the market including Pfizer Inc., Sanofi S.A., Shire Plc and Protalix BioTherapeutics, Inc.

Table of Content: Key Points
1. Market Overview
1.1 Lysosomal Storage Disease (LSD)
1.2 Classification of LSD
1.3 Symptoms
1.4 Diagnosis
1.5 Treatment
1.6 Upcoming Treatment
2. 2. Global LSD Market Analysis
2.1 Global LSD Market Forecast by Value
2.2 Global LSD Market Value by Category
2.3 Global Fabry Disease Market Forecast by Value
2.4 Global Fabry Disease Market Value by Drugs
2.5 Global Gaucher Disease Market Forecast by Value
2.6 Global Gaucher Disease Market Value by Drugs
2.7 Global Pompe Disease Market Forecast by Value
2.8 Global Pompe Disease Market Value by Drugs
3. Market Dynamics
3.1 Growth Drivers
3.2 Key Trends & Developments
3.3 Challenges
4. Competitive Landscape
4.1 Global Market
5. Company Profiles
5.1 Pfizer Inc.
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/3080299-global-lysosomal-storage-disease-lsd-market-fabry-gaucher

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.